A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study

References

• Jaffe E S, Harris N L, Stein H. Tumours of the Haemopoitic and Lymphoid Tissues. IARC Press, Lyon 2001
   Google Scholar
• Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and TTF, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984–1992
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, et al. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 2007, CD003805
   Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood 2005; 105: 2677–2684
   PubMed Web of Science ®Google Scholar
• Khouri I F, Lee M S, Saliba R M, Jun G, Fayad L, Younes A, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21: 4407–4412
   PubMed Web of Science ®Google Scholar
• Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13–21
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349–360
   PubMed Web of Science ®Google Scholar
• Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005; 23: 6364–6369
   PubMed Web of Science ®Google Scholar
• O'Connor O A, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676–684
   PubMed Web of Science ®Google Scholar
• Goy A, Younes A, McLaughlin P, Pro B, Romaguera J E, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667–675
   PubMed Web of Science ®Google Scholar
• Belch A, Kouroukis C T, Crump M, Sehn L, Gascoyne R D, Klasa R, et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007; 18: 116–121
   PubMed Web of Science ®Google Scholar
• Strauss S J, Maharaj L, Hoare S, Johnson P W, Radford J A, Vinnecombe S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor α response with clinical activity. J Clin Oncol 2006; 24: 2105–2112
   PubMed Web of Science ®Google Scholar
• Fisher R I, Bernstein S H, Kahl B S, Djulbegovic B, Robertson M J, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867–4874
   PubMed Web of Science ®Google Scholar
• Leonard J, Furman R, Cheung Y-K, J. F E, Cho H J, Vose J, et al. Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large b cell (DLBCL) and mantle cell lymphoma (MCL): phase I results. Blood 2005; 106: 147a
   Web of Science ®Google Scholar
• Dunleavy K, Janik J, Wilson W. Phase I/II study of bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma [abstract]. Blood 2004; 104, abstract no. 1385
   Web of Science ®Google Scholar
• Mounier N, Ribrag V, Haioun C, Salles G, Golfier J, Ertault M, et al. Efficacy and toxicity of two schedules of R-CHOP plus bortezomib in front-line B lymphoma patients: a randomized phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). J Clin Oncol 2007; 25, abstract no. 8010
   Google Scholar
• Gerecitano J, Portlock C, Noy A, Hamlin P, Moskowitz C, Straus D, et al. The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders. Blood 2006; 108, abstract no. 2759
   Web of Science ®Google Scholar
• Romaguera J, Fayad L, McLaughlin P, Pro B, Rodriguez A, Wang M, et al. Phase I trial of bortezomib in combination with rituximab-hyperCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma. Blood 2008; 112: 1049a
   Web of Science ®Google Scholar
• Weigert O, Pastore A, Rieken M, Lang N, Hiddemann W, Dreyling M, et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007; 21: 524–528
   PubMed Web of Science ®Google Scholar
• Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6: 257–262
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S, et al. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol 1983; 1: 689–694
   PubMed Web of Science ®Google Scholar
• Khouri I F, Romaguera J, Kantarjian H, Palmer J L, Pugh W C, Korbling M, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803–3809
   PubMed Web of Science ®Google Scholar
• Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587–593
   PubMed Web of Science ®Google Scholar
• de Guibert S, Jaccard A, Bernard M, Turlure P, Bordessoule D, Lamy T. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 2006; 91: 425–426
   PubMed Web of Science ®Google Scholar
• Romaguera J E, Fayad L, Rodriguez M A, Broglio K R, Hagemeister F B, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce M A, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008; 19: 1327–1330
   PubMed Web of Science ®Google Scholar
• Rummel M J, Al-Batran S E, Kim S Z, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383–3389
   PubMed Web of Science ®Google Scholar
• Robinson K S, Williams M E, van der Jagt R H, Cohen P, Herst J A, Tulpule A, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473–4479
   PubMed Web of Science ®Google Scholar
• Weide R, Hess G, Koppler H, Heymanns J, Thomalla J, Aldaoud A, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007; 48: 1299–1306
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Gutierrez A, Palacios A, Navarrete M, Blancas I, Alarcon J, et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 2007; 48: 2172–2178
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G, et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 2007; 18: 370–375
   PubMed Web of Science ®Google Scholar
• Wang M, Han X H, Zhang L, Yang J, Qian J F, Shi Y K, et al. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia 2008; 22: 179–185
   PubMed Web of Science ®Google Scholar